Patients with marginal zone dural lymphoma successfully treated with rituximab and bendamustine: A report of two cases

Tsutsumi,Yutaka; Ito,Shinichi; Nagai,Jun; Tateno,Takahiro; Teshima,Takanori

doi:10.3892/mco.2021.2371

October-2021 Volume 15 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October-2021 Volume 15 Issue 4

Full Size Image

Case Report Open Access

Patients with marginal zone dural lymphoma successfully treated with rituximab and bendamustine: A report of two cases

Authors:
- Yutaka Tsutsumi
- Shinichi Ito
- Jun Nagai
- Takahiro Tateno
- Takanori Teshima
View Affiliations / Copyright

Affiliations: Department of Hematology, Hakodate Municipal Hospital, Hakodate, Hokkaido 041‑8680, Japan, Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060‑8638, Japan

Copyright: © Tsutsumi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 208
|
Published online on: August 9, 2021

https://doi.org/10.3892/mco.2021.2371
Expand metrics +

Abstract

Primary dural low‑grade marginal zone B‑cell lymphoma of mucosa‑associated lymphoid tissue (MALT) is a rare disease whose main treatment has been local surgery or radiotherapy. Until now, there have been no cases of dural MALT lymphoma treatment of a patient with several relapses or systemic disease. The present study included two patients with dural MALT lymphoma who had several relapses or systemic disease. Since local therapy was not enough to control the disease for these patients, they were treated with systemic chemotherapy. The patients were administered rituximab (375 mg/m²) and two days of bendamustine (90 mg/m²). Both patients recovered from their clinical symptoms immediately, and their tumors were reduced. During and after rituximab and bendamustine therapy, no central nervous system (CNS) metastasis or cerebrospinal fluid invasion of MALT were observed. The current approach using rituximab and bendamustine treatment was effective against dural MALT lymphoma and may prevent its invasion of the CNS.

View Figures

View References

1	Ayanambakkam A, Ibrahimi S, Bilal K and Cherry MA: Extranodal marginal zone lymphoma of central nervous system. Clin Lymphoma Myeloma Leuk. 18:34–37.e8. 2018.PubMed/NCBI View Article : Google Scholar
2	Iwamoto FM and Abrey LE: Primary dural lymphoma: A review. Neurosurg Focus. 21(E5)2006.PubMed/NCBI View Article : Google Scholar
3	de la Fuente MI, Haggiagi A, Moul A, Young RJ, Sidani C, Markoe A, Vega F, DeAngelis LM and Lossos IS: Marginal zone dural lymphoma: The memorial sloan kettering cancer center and university of miami experience. Leuk Lymphoma. 58:882–888. 2017.PubMed/NCBI View Article : Google Scholar
4	Bustoros M, Liechty B, Zagzag D, Liu C, Shepherd T, Gruber D, Raphael B and Placantonakis DG: A rare case of composite dural extranodal marginal zone lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. Front Neurol. 9(267)2018.PubMed/NCBI View Article : Google Scholar
5	Salar A, Domingo-Domenech E, Panizo C, Nicolas C, Bargay J, Muntanola A, Canales M, Bello JL, Sancho JM, Tomas JF, et al: First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial. Lancet Haematol. 1:e104–e111. 2014.PubMed/NCBI View Article : Google Scholar
6	Kim T, Choi HY, Lee HS, Jung SH, Ahn JS, Kim HJ, Lee JJ, Yoo HD and Yang DH: Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL). BMC Cancer. 18(729)2018.PubMed/NCBI View Article : Google Scholar
7	Li Z, Caulfield T, Qiu Y, Copland JA and Tun HW: Pharmacokinetics of bendamustine in the central nervous system: Chemoinformatic screening followed by validation in a murine model. Med Chem Commun. 3:1526–1530. 2012.
8	Lim T, Kim SJ, Kim K, Lee JI, Lim DH, Lee DJ, Baek K, Lee HY, Han B, Uhm JE, et al: Primary CNS lymphoma other than DLBCL: A descriptive analysis of clinical features and treatment outcomes. Ann Hematol. 90:1391–1398. 2011.PubMed/NCBI View Article : Google Scholar
9	Chamberlain MC: Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: A retrospective case series. J Neurooncol. 118:155–162. 2014.PubMed/NCBI View Article : Google Scholar
10	Renfrow JJ, Detroye A, Chan M, Tatter S, Ellis T, McMullen K, Johnson A, Mott R and Lesser GJ: Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: A case report. J Neurooncol. 107:659–663. 2012.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Patients with marginal zone dural lymphoma successfully treated with rituximab and bendamustine: A report of two cases

This article is mentioned in:

Abstract

Figure 1

Related Articles